Skip to main content
TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.080
-0.010 (-0.92%)
At close: Dec 5, 2025, 4:00 PM EST
1.090
+0.010 (0.94%)
After-hours: Dec 5, 2025, 7:55 PM EST

TScan Therapeutics Revenue

TScan Therapeutics had revenue of $2.51M in the quarter ending September 30, 2025, with 139.37% growth. This brings the company's revenue in the last twelve months to $8.42M, down -10.03% year-over-year. In the year 2024, TScan Therapeutics had annual revenue of $2.82M, down -86.62%.

Revenue (ttm)
$8.42M
Revenue Growth
-10.03%
P/S Ratio
7.28
Revenue / Employee
$43,195
Employees
195
Market Cap
61.29M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20242.82M-18.23M-86.62%
Dec 31, 202321.05M7.51M55.52%
Dec 31, 202213.54M3.39M33.47%
Dec 31, 202110.14M9.06M834.65%
Dec 31, 20201.09M--
Dec 31, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 435.16B
Johnson & Johnson 92.15B
Merck & Co. 64.24B
AbbVie 59.64B
Eli Lilly and Company 59.42B
AstraZeneca 58.13B
Novartis AG 56.37B
Novo Nordisk 49.58B
Revenue Rankings

TCRX News

More News